Recurrent Lymphoblastic Lymphoma
1 clinical trials · Condition
◉ Watch Recurrent Lymphoblastic Lymphoma
| Record | Firm | Date |
|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (NCT07166419) | Ohio State University Comprehensive Cancer Center | 2026-01-14 |
Track Recurrent Lymphoblastic Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.